Search This Blog

Monday, December 30, 2019

Myriad up on FDA nod for test as Lynparza companion diagnostic

Myriad Genetics (NASDAQ:MYGN) is up 6% premarket on modest volume in reaction to the FDA nod for its BRACAnalysis CDx test as a companion diagnostic for AstraZeneca (NYSE:AZN) and Merck’s (NYSE:MRK) Lynparza (olaparib) for BRCA-mutated metastatic pancreatic cancer.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)